Since some small molecules that specifically target ERK1/2-ARF6-DUSP6 axis have exhibited potential clinical application value, our findings might provide new strategies for the comprehensive treatment of pancreatic cancer. This evidence concerns the gene MAPK3 and familial pancreatic carcinoma.